BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fumagalli V, Di Lucia P, Venzin V, Bono EB, Jordan R, Frey CR, Delaney W, Chisari FV, Guidotti LG, Iannacone M. Serum HBsAg clearance has minimal impact on CD8+ T cell responses in mouse models of HBV infection. J Exp Med 2020;217:e20200298. [PMID: 32761167 DOI: 10.1084/jem.20200298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bertoletti A, Boni C. HBV antigens quantity: duration and effect on functional cure. Gut 2021:gutjnl-2021-326258. [PMID: 34799373 DOI: 10.1136/gutjnl-2021-326258] [Reference Citation Analysis]
3 Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 2021. [PMID: 34002067 DOI: 10.1038/s41577-021-00549-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Wu S, Yi W, Gao Y, Deng W, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Shen G, Hu L, Zhang L, Li M, Xie Y. Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection. Front Immunol 2022;13:893512. [PMID: 35634301 DOI: 10.3389/fimmu.2022.893512] [Reference Citation Analysis]
5 Iannacone M, Andreata F, Guidotti LG. Immunological insights in the treatment of chronic hepatitis B. Curr Opin Immunol 2022;77:102207. [PMID: 35588690 DOI: 10.1016/j.coi.2022.102207] [Reference Citation Analysis]
6 Han JW, Shin EC. Liver-Resident Memory CD8+ T Cells: Possible Roles in Chronic HBV Infection. Int J Mol Sci 2020;22:E283. [PMID: 33396596 DOI: 10.3390/ijms22010283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Masemann D, Ludwig S, Boergeling Y. Advances in Transgenic Mouse Models to Study Infections by Human Pathogenic Viruses. Int J Mol Sci 2020;21:E9289. [PMID: 33291453 DOI: 10.3390/ijms21239289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 De Simone G, Andreata F, Bleriot C, Fumagalli V, Laura C, Garcia-Manteiga JM, Di Lucia P, Gilotto S, Ficht X, De Ponti FF, Bono EB, Giustini L, Ambrosi G, Mainetti M, Zordan P, Bénéchet AP, Ravà M, Chakarov S, Moalli F, Bajenoff M, Guidotti LG, Ginhoux F, Iannacone M. Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming. Immunity 2021;54:2089-2100.e8. [PMID: 34469774 DOI: 10.1016/j.immuni.2021.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Lang-Meli J, Neumann-Haefelin C, Thimme R. Immunotherapy and therapeutic vaccines for chronic HBV infection. Curr Opin Virol 2021;51:149-57. [PMID: 34710645 DOI: 10.1016/j.coviro.2021.10.002] [Reference Citation Analysis]
10 Kuipery A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, Janssen HLA, Gehring AJ. Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T-cell recognition of infected HepG2-NTCP. Hepatology 2022;75:1539-50. [PMID: 34743340 DOI: 10.1002/hep.32230] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang X, Wang X, Wu M, Ghildyal R, Yuan Z. Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future. Front Microbiol 2021;12:715450. [PMID: 34335553 DOI: 10.3389/fmicb.2021.715450] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Knolle PA, Huang LR, Kosinska A, Wohlleber D, Protzer U. Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection. Vaccines (Basel) 2021;9:1333. [PMID: 34835264 DOI: 10.3390/vaccines9111333] [Reference Citation Analysis]
13 Zhang C, Li J, Cheng Y, Meng F, Song JW, Fan X, Fan H, Li J, Fu YL, Zhou MJ, Hu W, Wang SY, Fu YJ, Zhang JY, Xu RN, Shi M, Hu X, Zhang Z, Ren X, Wang FS. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut 2022:gutjnl-2021-325915. [PMID: 35361683 DOI: 10.1136/gutjnl-2021-325915] [Reference Citation Analysis]
14 Yang S, Zeng W, Zhang J, Lu F, Chang J, Guo JT. Restoration of a functional antiviral immune response to chronic HBV infection by reducing viral antigen load: if not sufficient, is it necessary? Emerg Microbes Infect 2021;10:1545-54. [PMID: 34227927 DOI: 10.1080/22221751.2021.1952851] [Reference Citation Analysis]
15 Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft ARM, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 2021:gutjnl-2021-324646. [PMID: 34702717 DOI: 10.1136/gutjnl-2021-324646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
16 Iannacone M, Guidotti LG. Developing a cure for chronic hepatitis B requires a fresh approach. Nature 2022;603:S49. [PMID: 35354983 DOI: 10.1038/d41586-022-00813-0] [Reference Citation Analysis]